Clinical Trials Browser

Phase 1/2 × Sarcoma × Tiragolumab × Clear all

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase 1/2 Active not recruiting

Chordoma, Sarcoma, Rhabdoid Tumor